Long‐term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab

BACKGROUND: Blinatumomab is a CD19 BiTE (bispecific T‐cell engager) immuno‐oncology therapy that mediates the lysis of cells expressing CD19. METHODS: A pooled analysis of long‐term follow‐up data from 2 phase 2 studies that evaluated blinatumomab in heavily pretreated adults with Philadelphia chrom...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer
Main Authors: Topp, Max S., Gökbuget, Nicola, Zugmaier, Gerhard, Stein, Anthony S., Dombret, Hervé, Chen, Yuqi, Ribera, Josep‐Maria, Bargou, Ralf C., Horst, Heinz‐August, Kantarjian, Hagop M.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2020
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7894150/
https://ncbi.nlm.nih.gov/pubmed/33141929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.33298
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares